MANATT, PHELPS, AND PHILLIPS

Lobbying for DENALI THERAPEUTICS · Biopharmaceutical Company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · California · $70,000.00 income · posted Apr 6, 2026

Lobbying activity 1

Health Issues

Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Rare disease drug development

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.